| Literature DB >> 23800277 |
Basma Mnif1, Hela Harhour, Jihène Jdidi, Faouzia Mahjoubi, Nathalie Genel, Guillaume Arlet, Adnene Hammami.
Abstract
BACKGROUND: Extended-spectrum β-lactamases (ESBLs), particularly CTX-M- type ESBLs, are among the most important resistance determinants spreading worldwide in Enterobacteriaceae. The aim of this study was to characterize a collection of 163 ESBL-producing Escherichia coli collected in Tunisia, their ESBL-encoding plasmids and plasmid associated addiction systems.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23800277 PMCID: PMC3701463 DOI: 10.1186/1471-2180-13-147
Source DB: PubMed Journal: BMC Microbiol ISSN: 1471-2180 Impact factor: 3.605
Figure 1Evolution of SHV and CTX-M ESBL type incidence during the study period.
Number of replicons according to ESBL type identified in the -recipient strains
| All | |||||||||||||
| 0 | 0 | 0 | 0 | 0 | |||||||||
| TEM-26 | 2 | | | | | | | | | 2 | | | |
| 0 | 3 | 5 | 3 | 1 | |||||||||
| SHV-2a | 9 | 1 | | | | | 1 | 2 | | 1 | 4 | 1 | |
| SHV-12 | 30 | 9 | | 3 | 5 | 3 | | 12 | | 1 | 1 | 1 | 4 |
| CTX-M-14 | 15 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 0 | 0 | 9 |
| CTX-M-15 | 88 | 72† | 48 | 2 | 4 | 15 | 3 | 2 | 3 | 7† | 0 | 2 | 2 |
ND not determined.
*: p < 0.05 for CTX-M ESBLs vs. non CTX-M ESBLs.
†: p < 0.05 for CTX-M-15 ESBL vs. other ESBLs.
Phylogenetic groups of ESBL-producing isolates
| Total number | 163 (%) | 118 | 45 | 101 |
| A | 54 (33.1) | 34 | 20 | 26 |
| B1 | 24 (14.7) | 12 | 12 | 10 |
| B2 | 61 (37.4) | 55 † | 6 | 52 √ |
| D | 24 (14.7) | 17 | 7 | 13 |
†: p < 0.0005 for CTX-M B2 producers vs no CTX-M B2 producers.
√: p < 0.0005 for CTX-M-15 B2 producers vs no CTX-M-15 B2 producers.
Figure 2XbaI-PFGE dendrogram for 22 CXT-M-15-positive isolates from ST131 and a representative ST131 strain from France.
Distribution of virulence genes (%) in ESBL-producing isolates
| Total | 910 | 730 | 180 | 671 | 463 | 332 | 193 | 186 |
| Mean | 5.58 | 6.18 | 4.0 | 6.64 | 8.90 | 8.97 | 8.04 | 8.08 |
| Adhesin | 3 (1.8) | 2 (1.6) | 1 (2.2) | 2 (1.9) | - | 1 (2.7) | - | - |
| 21 (12.8) | 19 (16.1) * | 2 (4.4) | 19 (18.8)‡ | 15 (28.8) † | 10 (27.2) | 5 (20.8) | 5 (21.7) | |
| 36 (22.0) | 30 (25.4) | 6 (13.3) | 30 (29.7) ‡ | 25 (48.0) † | 24 (64.8) γ | 4 (16.6) | 4 (17.3) | |
| 35 (21.4) | 29 (24.5) | 6 (13.3) | 29 (28.7) ‡ | 25 (48.0) † | 25 (67.5) γ | 3 (12.5) | 3 (13) | |
| 138 (84.7) | 100 (84.7) | 38 (84.4) | 85 (84.2) | 51 (98.1) † | 36 (97.3) | 24 (100) | 23 (100) | |
| 8 (4.9) | 4 (3.3) | 4 (8.8) | 4 (3.9) | 2 (3.8) | 3 (8.1) | 1 (4.1) | 1 (4.3) | |
| 26 (15.9) | 20 (16.9) | 6 (13.3) | 20 (19.8) ‡ | 18 (34.6) † | 22 (59.4) γ | - | - | |
| 49 (30.0) | 45 (38.1) * | 4 (8.8) | 43 (42.5) ‡ | 36 (69.2) † | 14 (37.8) γ | 24 (100) | 23 (100) | |
| 38 (23.3) | 29 (24.5) | 9 (20.0) | 28 (27.7) | 19 (36.5) † | 24 (64.8) γ | - | - | |
| Iron uptake | 104 (63.8) | 78 (66.1) | 26 (57.7) | 68 (67.3) | 49 (94.2) † | 33 (89.1) | 24 (100) | 23 (100) |
| 82 (50.3) | 65 (55.0) * | 17 (37.7) | 60 (59.4) ‡ | 37 (71.2) † | 16 (43.2) γ | 24 (100) | 23 (100) | |
| Toxin | 27 (16.5) | 24 (20.3) * | 3 (6.6) | 23 (22.8) ‡ | 22 (42.3) † | 24 (64.9) γ | 2 (8.3) | 2 (8.6) |
| 19 (11.6) | 17 (14.4) | 2 (4.4) | 17 (16.8) ‡ | 14 (26.9) † | 15 (40.5) γ | - | - | |
| 38 (23.3) | 37 (31.3) * | 1 (2.2) | 35 (34.6) ‡ | 30 (57.6) † | 8 (21.6) γ | 24 (100) | 23 (100) | |
| Cell protection | 119 (73.0) | 94 (79.6) * | 25 (55.5) | 84 (83.2) ‡ | 40 (76.9) | 28 (75.5) | 18 (75) | 18 (78.2) |
| 69 (42.3) | 64 (54.2) * | 5 (11.1) | 59 (58.4) ‡ | 45 (86.5) † | 27 (72.9) γ | 23 (95.8) | 22 (95.6) | |
| Other | 98 (60.1) | 73 (61.8) | 25 (55.5) | 65 (64.3) | 35 (67.3) | 22 (59.4) | 17 (70.8) | 16 (69.5) |
*: p < 0.05 for CTX-M producers vs. non CTX-M producers.
‡: p < 0.05 for CTX-M-15 producers vs. non CTX-M producers.
†: p < 0.05 for CTX-M-15 B2 producers vs. other phylogroup isolates with CTX-M-15.
γ: p < 0.05 for B2 non-ST131 isolates vs. B2 ST131 isolates.
Nature and number of addiction systems according to ESBL type and replicon type identified in the recipient strains
| | ||||||||
| SHV-2a | 9 | 1 | | | | | 1 | |
| SHV-12 | 30 | 11 | 9 | 7 | 0 | 3 | 30 | |
| CTX-M-14 | 15 | 6 | 0 | 0 | 2 | 0 | 8 | 0.53 |
| CTX-M-15 | 88 | 64 | 20 | 44 | 3 | 15 | 143 | 1.62 |
| Total | Meani | |||||||
| 0 | 0 | 0 | 0 | 0 | 0 | | ||
| 0 | 0 | 0 | 0 | 0 | 0 | | ||
| 0 | 0 | 0 | 0 | |||||
| 0 | 0 | 0 | 5 | |||||
| 0 | 0 | 9 | ||||||
| 0 | 0 | 0 | 0 | 2 | ||||
| SHV | 12 | 10 | 9 | 6 | 0 | 1 | 26 | 2.16 |
| CTX-M | 73 | 59 | 20 | 44 | 0 | 13 | 136 | 1.87 |
| | 1.51 | |||||||
| CTX-M-15 | 48 | | | | | 1 | | |
| | 1.25 | |||||||
| SHV-2a | 1 | 0 | 0 | 0 | 0 | 0 | | |
| CTX-M-15 | 3 | 2 | 1 | 2 | 0 | 0 | | |
| | 2.72 | |||||||
| SHV-12 | 3 | 3 | 2 | 3 | | 0 | | |
| CTX-M-15 | 15 | 12 | 12 | 9 | | 9 | | |
| | 2.55 | |||||||
| SHV-12 | 5 | 5 | 4 | 1 | | 1 | | |
| CTX-M-15 | 4 | 3 | 4 | 2 | | 3 | | |
| | 2.20 | |||||||
| SHV-12 | 3 | 2 | 3 | 2 | | | | |
| CTX-M15 | 2 | 2 | 2 | 0 | ||||
apemKI: CTX-M vs SHV, p < 0.001; CTX-M-15 vs other ESBLs, p < 0.001.
bhok-sok: CTX-M vs SHV, p < 0.01; CTX-M-15 vs other ESBLs, p < 0.001.
cvagCD: CTX-M vs SHV, p =0.23; CTX-M-15 vs other ESBLs, p = 0.03.
d Mean: CTX-M vs SHV, p <0.001; CTX-M-15 vs other ESBLs, p < 0.001.
epemKI: IncF vs other plasmids, p < 0.001.
fccdAB: IncF vs other plasmids, p < 0.001.
ghok-sok: IncF vs other plasmids, p < 0.001.
hvagCD: IncF vs other plasmids, p = 0.08, vagCD: IncF and IncI1 vs other plasmids, p = 0.01.
i Mean: IncF vs other plasmids, p < 0.001.